1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Japan To Reimburse Zolgensma – But At Lower Price Than US

NHI Scheme Grants Coverage

 
• By Ian Haydock

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Gene therapy
Gene Therapy Zolgensma Sets Price Record In Japan • Source: Shutterstock

Japan’s regulatory authorities have decided to grant reimbursement to Novartis AG/AveXis Inc.’s gene therapy Zolgensma (onasemnogene abeparvovec) under the national health insurance scheme, marking a watershed in drug pricing in the country, although the annualized cost will be less than many other big-selling products.

The decision also suggests a continued willingness in Japan to support novel therapies and gene therapies in particular, following the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.